{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:20:28Z","timestamp":1788848428124,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Medical and Health Science and Technology Plan 2025","award":["2025KY1407"],"award-info":[{"award-number":["2025KY1407"]}]},{"name":"Ningbo No.2 Hospital Key Discipline - Department of Hematologic and Oncology","award":["2023-Y08"],"award-info":[{"award-number":["2023-Y08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06912-6","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:45:45Z","timestamp":1772261145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low hemoglobin as a novel prognostic biomarker in EBV-positive diffuse large B-cell lymphoma patients: a clinical feature analysis of 99 cases from Zhejiang, Southeast China"],"prefix":"10.1007","volume":"105","author":[{"given":"Mengmeng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangfeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suying","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"issue":"22","key":"6912_CR1","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1182\/blood-2010-11-316745","volume":"117","author":"JI Cohen","year":"2011","unstructured":"Cohen JI et al (2011) Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 117(22):5835\u20135849","journal-title":"Blood"},{"issue":"7335","key":"6912_CR2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma. Lancet 1(7335):702\u2013703","journal-title":"Lancet"},{"key":"6912_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","volume":"14","author":"PJ Farrell","year":"2019","unstructured":"Farrell PJ (2019) Epstein-barr virus and cancer. Annu Rev Pathol 14:29\u201353","journal-title":"Annu Rev Pathol"},{"issue":"12","key":"6912_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","volume":"16","author":"LS Young","year":"2016","unstructured":"Young LS, Yap LF, Murray PG (2016) Epstein-barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer 16(12):789\u2013802","journal-title":"Nat Rev Cancer"},{"key":"6912_CR5","unstructured":"Padala SA, Kallam A (2024) Diffuse Large B-Cell Lymphoma, in StatPearls. Treasure Island (FL)"},{"issue":"7","key":"6912_CR6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ajh.26579","volume":"97","author":"L Malpica","year":"2022","unstructured":"Malpica L et al (2022) EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol 97(7):951\u2013965","journal-title":"Am J Hematol"},{"key":"6912_CR7","doi-asserted-by":"crossref","unstructured":"Malpica L et al (2024) EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management. Am J Hematol","DOI":"10.1002\/ajh.27430"},{"issue":"6","key":"6912_CR8","doi-asserted-by":"publisher","first-page":"e0199398","DOI":"10.1371\/journal.pone.0199398","volume":"13","author":"X Gao","year":"2018","unstructured":"Gao X et al (2018) Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis. PLoS ONE 13(6):e0199398","journal-title":"PLoS ONE"},{"issue":"9","key":"6912_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/PAS.0000000000001499","volume":"44","author":"S Miyagi","year":"2020","unstructured":"Miyagi S et al (2020) Reappraisal of Primary Epstein-Barr Virus (EBV)-positive Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract: Comparative Analysis Among Immunosuppressed and Nonimmunosuppressed Stage I and II-IV Patients. Am J Surg Pathol 44(9):1173\u20131183","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"6912_CR10","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","volume":"20","author":"CY Ok","year":"2014","unstructured":"Ok CY et al (2014) Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 20(9):2338\u20132349","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6912_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00005-015-0341-2","volume":"64","author":"M Ziarkiewicz","year":"2016","unstructured":"Ziarkiewicz M et al (2016) Epstein-Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland. Arch Immunol Ther Exp (Warsz) 64(2):159\u2013169","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"20","key":"6912_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"7","key":"6912_CR13","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7):1720\u20131748","journal-title":"Leukemia"},{"key":"6912_CR14","doi-asserted-by":"crossref","unstructured":"Hwang J et al (2021) The Incidence of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 13(8)","DOI":"10.3390\/cancers13081785"},{"issue":"14","key":"6912_CR15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329(14):987\u2013994","journal-title":"N Engl J Med"},{"issue":"17","key":"6912_CR16","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-06-2823","volume":"13","author":"T Oyama","year":"2007","unstructured":"Oyama T et al (2007) Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 13(17):5124\u20135132","journal-title":"Clin Cancer Res"},{"issue":"8","key":"6912_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/ajh.22078","volume":"86","author":"BE Beltran","year":"2011","unstructured":"Beltran BE et al (2011) EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol 86(8):663\u2013667","journal-title":"Am J Hematol"},{"issue":"3","key":"6912_CR18","first-page":"181","volume":"35","author":"K Matsumoto","year":"2018","unstructured":"Matsumoto K et al (2018) Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study. Turk J Haematol 35(3):181\u2013184","journal-title":"Turk J Haematol"},{"issue":"12","key":"6912_CR19","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/cas.12544","volume":"105","author":"J Hong","year":"2014","unstructured":"Hong J et al (2014) Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Cancer Sci 105(12):1569\u20131575","journal-title":"Cancer Sci"},{"issue":"1","key":"6912_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282","journal-title":"Blood"},{"issue":"9","key":"6912_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384(9):842\u2013858","journal-title":"N Engl J Med"},{"issue":"3","key":"6912_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2007-01-067769","volume":"110","author":"S Park","year":"2007","unstructured":"Park S et al (2007) The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110(3):972\u2013978","journal-title":"Blood"},{"issue":"12","key":"6912_CR23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/j.1440-1827.2009.02466.x","volume":"59","author":"Y Shimoyama","year":"2009","unstructured":"Shimoyama Y et al (2009) Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic approach to a newly recognized clinicopathological entity. Pathol Int 59(12):835\u2013843","journal-title":"Pathol Int"},{"issue":"11","key":"6912_CR24","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/cas.12812","volume":"106","author":"A Okamoto","year":"2015","unstructured":"Okamoto A et al (2015) Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma. Cancer Sci 106(11):1576\u20131581","journal-title":"Cancer Sci"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06912-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:39Z","timestamp":1776405519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06912-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6912"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06912-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a retrospective analysis of de-identified data collected as part of routine clinical care. No personally identifiable information was used. Given its retrospective nature and the absence of direct patient contact or intervention, this study was exempted from institutional review board (IRB) approval and the requirement for informed consent. The study was approved by the Ethics Committee of Ningbo No.2 Hospital (Approval NO.: PJ-NBEY-KY-2025-027-01) and was conducted following the principles of the Helsinki Declaration in its current version.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}